BLISSGVS — Bliss GVS Pharma Balance Sheet
0.000.00%
- IN₹16.07bn
- IN₹15.87bn
- IN₹8.10bn
- 70
- 34
- 84
- 72
Annual balance sheet for Bliss GVS Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 778 | 1,459 | 726 | 1,513 | 1,502 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,700 | 4,069 | 4,281 | 4,451 | 4,662 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 7,652 | 7,760 | 6,974 | 8,116 | 8,193 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,278 | 2,948 | 3,729 | 3,694 | 4,177 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 10,768 | 11,087 | 11,569 | 12,139 | 13,008 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,036 | 2,331 | 1,933 | 1,598 | 1,717 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,685 | 2,900 | 2,730 | 2,467 | 2,505 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 8,083 | 8,187 | 8,839 | 9,672 | 10,504 |
| Total Liabilities & Shareholders' Equity | 10,768 | 11,087 | 11,569 | 12,139 | 13,008 |
| Total Common Shares Outstanding |